China’s CDE Sets New Draft Regulatory Guidelines for mRNA Vaccines, DSUR Reporting and CAR-T Product Instructions

In September 2025, China’s Center for Drug Evaluation (CDE) released three draft guidance documents for public comment. They address pharmaceutical research for prophylactic mRNA vaccines, Development Safety Update Report (DSUR) submissions, and clinical information requirements for CAR-T product instructions.

For companies developing novel vaccines, running global clinical trials, or advancing cell therapies, the drafts provide clear direction on regulatory expectations that will shape future approval and market access in China.

Summaries and consultation timelines for each draft are below:

• (Draft) Technical Guidelines for Pharmaceutical Research on Prophylactic mRNA Vaccines 
  Released: 16 September 2025 | Consultation ends: 16 October 2025
• (Draft) Frequently Asked Questions on Development Safety Update Reports (DSURs)
  Released: 17 September 2025 | Consultation ends: 17 October 2025
• (Draft) Guidelines for Writing Clinical Information in CAR-T Product Instructions
  Released: 17 September 2025 | Consultation ends: 17 October 2025

Together, these drafts reflect China’s growing alignment with international regulatory norms and its focus on technical rigor and lifecycle quality management.

Prophylactic mRNA Vaccine Draft Technical Guidelines: Strengthened Quality and Lifecycle Controls 

Released on 16 September with consultation open until 16 October, the “Technical Guidelines for Pharmaceutical Research on Prophylactic mRNA Vaccines (Draft for Comments)” set out comprehensive technical requirements spanning the entire product lifecycle, from raw materials to finished product. Specifically, it emphasizes quality-by-design, impurity control, and robust stability testing.

The draft aligns with WHO and EMA guidance and encourages early alignment of manufacturing processes to reduce regulatory friction for overseas developers.

Key Focus Areas

• Source control and process design: Emphasises strict quality standards for starting materials (e.g., plasmid DNA, enzymes, lipids) and applies a quality-by-design approach to mRNA sequence design, modification, in vitro transcription, purification, and delivery system preparation.
• Critical quality attributes: Defines and controls critical attributes such as mRNA integrity, purity, poly(A) tail length, encapsulation efficiency, particle size distribution, and lipid composition.
• Integrated quality control strategy: Combines in-process controls and release testing, with sensitive methods for detecting product-related impurities such as double-stranded RNA and truncated mRNA, as well as process-related impurities such as residual DNA and solvents, with strict limits applied.
• Robust stability studies: Requires stability testing focused on mRNA chemical degradation and the physical stability of the delivery system, including long-term, accelerated, photostability, and freeze-thaw conditions to support appropriate storage and transport.
• Lifecycle quality management: Promotes continuous improvement of manufacturing processes and quality control methods, with ongoing refinement of standards as data and knowledge accumulate.

DSUR Reporting FAQs Draft: Greater Clarity for Global Clinical Sponsors 

The second draft, “Frequently Asked Questions on Development Safety Update Reports (DSUR) (Draft for Comments),” was released on 17 September, with consultation open until 17 October. This draft clarifies DSUR submission scope, timelines, and format under ICH E2F. In addition, it distinguishes DSURs from expedited reports and addresses common implementation challenges. 

The draft supports harmonisation with global DSUR cycles, helping multinational sponsors streamline workflows and reduce compliance risks. 

Key Clarifications 

• Scope and timelines: Defines which drugs and trial phases require DSUR submission, along with the relevant reporting periods and deadlines.
• Content and format: Clarifies expectations for DSUR sections under ICH E2F standards — especially areas commonly misunderstood in practice.
• DSURs vs. expedited reports: Emphasizes that both are complementary tools for safety monitoring, not substitutes for one another.
• Practical implementation: Offers guidance on setting the reporting start date, evaluating global marketing status, and applying DSURs to centralized monitoring projects.

CAR-T Product Instructions Draft Guidelines: Structured Clinical Documentation 

Also released on 17 September, the “Guidelines for Writing Clinical Information in CAR-T Product Instructions (Draft for Comments)” introduce a standardised framework for writing the “Clinical Information” section of Chimeric Antigen Receptor T Cell (CAR-T) product instructions, improving clarity and usability for clinical decision-making.

 The draft reflects China’s move toward FDA-style clarity in cell therapy documentation, supporting safer clinical use and faster regulatory review. 

Core Requirements 

• Dosage and administration: Detailed guidance on pre-infusion lymphodepletion chemotherapy regimens, infusion procedures, dosing, and key operational considerations to ensure standardised administration.
• Safety information: Prominent presentation of adverse reactions specific to CAR-T therapies such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), with grading and management protocols.
• Efficacy data: Clear presentation of clinical results, such as response rates and duration, as well as study limitations, including follow-up duration and population characteristics.
• Special populations: Clear guidance for patients with hepatic or renal impairment and elderly patients, even when data are limited. 
• Medication error prevention: Warnings covering the entire handling chain from identification and transport to thawing and infusion. 

Next Steps for Companies 

With the drafts offering a look at China’s evolving regulatory expectations, companies should use this consultation period to prepare strategically. Taking proactive steps now will help ensure a smoother transition once the guidelines are finalised. 

Recommended actions include: 

1. Reviewing the drafts carefully to assess their potential impact on development, quality, and clinical strategies. 
2. Submitting targeted feedback during the consultation period to clarify uncertainties and raise practical considerations.
3. Monitoring CDE updates closely to track revisions and prepare for implementation once finalized. 

The Bottom Line

These three draft guidelines offer an early indication of China’s regulatory direction: greater scientific rigor, closer alignment with international standards, and stronger lifecycle oversight. Whether domestic or international, companies involved in pharmaceutical development or clinical trials should review the drafts and consider their strategic implications. Engaging with the consultation process and assessing internal development, quality, and clinical strategies in light of the draft requirements can help reduce future regulatory friction and support readiness once the guidelines are finalised. 

With over 20 years of on-the-ground experience navigating China’s regulatory environment, Cisema delivers end-to-end solutions for life sciences companies — from strategic planning and dossier preparation to product registration and post-market compliance. 

For tailored insights on how these draft guidelines will shape your regulatory strategy in China, get in touch with Cisema today.

Further Information

Visit our Pharmaceutical Consulting Services page to learn more about how Cisema can support your regulatory strategy in China. 

References 

For more details, you can read the original announcements in Simplified Chinese on the CDE website. 

• 《预防用mRNA疫苗药学研究技术指导原则（征求意见稿）》核心内容 
• 《研发期间安全性更新报告常见问答（征求意见稿）》核心内容 
• 《嵌合抗原受体T细胞说明书临床相关信息撰写指导原则（征求意见稿）》核心内容